why is bpc 157 not fda approved BPC-157 — the most prescribed peptide you've never seen in a clinical trial. 30 total human subjects. Zero RCTs. A Phase 1 that was registered, enrolled, and then quietly canceled with no Peptides: What they are, potential
Description
Only one involved humans: a small, uncontrolled retrospective study of 12 patients with knee pain

Expression of miR-625-3p can be inhibited by mTOR inhibitor rapamycin, then influencing CD8+ T cell proliferation and functions that mediating the anti-viral immunity and graft-vs.-host-disease (GVHD) in SCT patients

Unlike most of the peptides listed here, it has actually gone through the full process of getting FDA approval, in this case to treat Barth syndrome, a condition caused by malfunctioning mitochondria

In this multicenter study, data of 1327 subjects were obtained, and the analysis showed a reduction in the Visual Analog Scale (VAS) score for pain by the 4th week in 74% of subjects, with 82% of subjects reporting good to excellent tolerability
patients with autoimmune gastritis or pernicious anemia

All treatments are provided under medical supervision and in accordance with applicable federal and state regulations